The use of a succinate-containing infusion solution in patients with a new coronavirus infection promotes a more rapid and sustainable correction of COVID-19-associated endotheliopathy, which, in turn, is manifested by a decrease in the levels of endotheliocytosis, secondary markers of endotheliopathy, a platelet-protective effect and a decrease in heparin resistance.

Clinical and laboratory parameters of 53 patients in the intensive care unit with COVID-19 complicated by community-acquired bilateral polysegmental pneumonia were analyzed.

The intensive care package for 27 patients (study group) included a daily infusion of a 1.5% solution of meglumine sodium succinate (Reamberin) in a daily dose of up to 10 ml/kg for a course of at least 11 days or during the entire stay in the department.

Read More